Recent Finacing
Recent Raise
Endeavor BioMedicines is a clinical-stage biotech developing ENV-101 (taladegib), a Hedgehog-pathway inhibitor for IPF, PPF and oncology, plus ENV-501 ADC and autophagy-targeting programs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Endeavor BioMedicines.
